The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial, SAP-001 significantly reduce uric acid . SAP-001 was well tolerated.
– Established China Biotechnology Company with Global Headquarters in the United States – Proceeds will advance clinical development of SAP-001 clinical trials for hyperuricemia and gout Based in Shanghai, Shanton Pharma is a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, closed a $31.2 million Series A+ financing in December of 2020. The proceeds will be used to accelerate the p